Allogeneic T Cell Therapies Market Report 2025

The allogeneic t cell therapies market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to regulatory approvals, increasing cancer prevalence, rising clinical trials, government funding, and a growing geriatric population.

The allogeneic t cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to expanding indications, rising demand for cell-based immunotherapies, growing awareness about advanced therapies, increasing healthcare expenditure, and supportive reimbursement policies. Major trends in the forecast period include advancement in research and development activities, personalized medicine, off-the-shelf therapies, global market expansion, strategic partnerships, and regulatory landscape evolution.

The forecast of 9.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cancer centers by driving up costs of donor-derived T cell therapies imported from the UK and Switzerland, exacerbating immunotherapy program expenses and increasing hematologic malignancy treatment burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing incidence of cancer is expected to drive the expansion of the allogeneic T cell therapies market. Cancer is a group of diseases marked by the uncontrolled proliferation and spread of abnormal cells in the body. The rise in cancer cases is linked to factors such as increased life expectancy, lifestyle changes, environmental exposures, infections, genetic predispositions, and shifts in reproductive patterns, all of which contribute to a higher incidence and detection of cancer. Allogeneic T cell therapies, which involve infusing genetically engineered donor T cells to target and destroy cancer cells, are increasingly being used in cancer treatment. According to the National Cancer Institute in May 2024, there were approximately 18.1 million cancer survivors in the U.S., a number projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths rising to 15.3 million. These trends are expected to propel the growth of the allogeneic T cell therapies market.

Leading companies in the allogeneic T cell therapies market are focusing on developing innovative chimeric antigen receptor (CAR) T-cell therapy programs to enhance treatment effectiveness and broaden therapeutic options. These advanced initiatives aim to improve the efficiency, accessibility, and delivery of CAR T-cell therapies for cancer. For example, in October 2022, Allogene Therapeutics Inc., a U.S.-based biotechnology company, launched CAR T Together, an initiative aimed at addressing challenges related to the delivery and accessibility of CAR T therapies. The program seeks to streamline clinical trial enrollment and foster collaboration among oncologists to expedite the development of allogeneic CAR T therapies. Unlike autologous therapies, which use a patient's own cells, allogeneic therapies rely on T cells from healthy donors, allowing for more efficient manufacturing processes.

In January 2023, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed sum. This acquisition is part of AstraZeneca’s strategy to advance innovative treatments and bolster its oncology capabilities, particularly in developing therapies for solid tumors that target cancer-specific mutations. Neogene Therapeutics Inc. is a U.S.-based biotechnology firm specializing in allogeneic T cell therapies.

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc, Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc, Bellicum Pharmaceuticals Inc.

North America was the largest region in the allogeneic T cell therapies market in 2023. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allogeneic t cell therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The allogeneic T cell therapies market research report is one of a series of new reports that provides allogeneic T cell therapies market statistics, including the allogeneic T cell therapies industry's global market size, regional shares, competitors with an allogeneic T cell therapies market share, detailed allogeneic T cell therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the allogeneic T cell therapies industry. This allogeneic T cell therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Allogeneic T cell therapies represent an advanced medical approach where T cells, critical to the immune system, are sourced from a donor and utilized to attack cancer cells in a recipient. These therapies are primarily applied in the treatment of challenging cancers that are resistant to conventional therapies.

The key forms of allogeneic T cell therapies include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. CAR T-cell therapies are a type of immunotherapy where T-cells are genetically engineered to target and eliminate cancer cells by recognizing specific proteins on them. Targeted antigens in these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, among others. These therapies address various conditions such as cancer, autoimmune disorders, and infectious diseases, with applications spanning hospitals, specialty clinics, research institutions, and other healthcare facilities.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.